	US 12,226,482 B2
	Anti-SIRP-alpha antibodies and methods of use thereof
Andrew Pincetic, San Francisco, CA (US); Arnon Rosenthal, Woodside, CA (US); and Seung-Joo Lee, South San Francisco, CA (US)
Assigned to Alector LLC, South San Francisco, CA (US)
Filed by Alector LLC, South San Francisco, CA (US)
Filed on Aug. 23, 2023, as Appl. No. 18/454,286.
Application 18/454,286 is a division of application No. 16/463,062, granted, now 11,779,642, previously published as PCT/US2017/065366, filed on Dec. 8, 2017.
Claims priority of provisional application 62/432,503, filed on Dec. 9, 2016.
Prior Publication US 2024/0082395 A1, Mar. 14, 2024
Int. Cl. A61K 39/395 (2006.01); A61P 31/00 (2006.01); A61P 35/00 (2006.01); C07K 16/28 (2006.01)

CPC A61K 39/39558 (2013.01) [A61P 31/00 (2018.01); A61P 35/00 (2018.01); C07K 16/2803 (2013.01); C07K 2317/24 (2013.01); C07K 2317/732 (2013.01); C07K 2317/75 (2013.01); C07K 2317/76 (2013.01); C07K 2317/77 (2013.01); C07K 2317/92 (2013.01)]

19 Claims

1. An isolated anti-signal regulatory protein a (SIRPA) antibody, wherein the anti-SIRPA antibody comprises a heavy chain variable region (VH) that comprises a complementarity determining region 1 (CDR1) comprising the amino acid sequence of SEQ ID NO: 15, a CDR2 comprising the amino acid sequence of SEQ ID NO: 16, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 17; and a light chain variable region (VL) that comprises a CDR1 comprising the amino acid sequence of SEQ ID NO: 12, a CDR2 comprising the amino acid sequence of SEQ ID NO: 13, and a CDR3 comprising the amino acid sequence of SEQ ID NO: 14.